Abstract: One strategy in the search for a pharmacotherapy for cocaine abuse and dependence has been to use drugs with a similar mechanism of action as cocaine, or agonist substitution therapy. Research has indicated that cocaine's behavioral effects are primarily a result of its blockade of the dopamine (DA), serotonin (5-HT) and norepinephrine (NE) transporters. Therefore, drugs that act either directly or indirectly at these monoamine systems have been investigated for their potential as replacement medications for cocaine addiction. The intent of this review was to present data from animal models that assessed the reinforcing effects of these monoamine agonists using drug self-administration, and the rewarding effects, using the conditioned place preference paradigm. Those data were then compared to the abuse liability of the selected drugs in humans and to their efficacy as therapeutics for treating cocaine addiction to determine if animal models of reinforcing and rewarding effects were predictive of these drugs' effects in humans. Fourteen drugs with a primary mechanism of action at either the DA, 5-HT or NE systems were identified that had been tested as potential treatments for cocaine addiction and had also been evaluated in either the self-administration or conditioned place preference paradigms in animals. From these comparisons, it was concluded that the animal models were, in general, predictive of the abuse liability of these monoamine agonists in humans. However, monoamine agonists with reinforcing or rewarding effects did not affect the desired treatment outcomes for cocaine addiction.
I. INTRODUCTION
At the turn of this century, approximately 1.2 million Americans reported using cocaine at least once per month [1] . While the current percentage of cocaine users is not as high as for other illicit drugs, cocaine addiction results in considerable health and financial losses that exceed other drugs. Over the course of an 8-year period (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) , an average of 47 billion dollars per year was spent on the purchase of cocaine in this country [2] , the highest of any illicit drug. In one year's time (1992) the total economic cost in the U.S. due to illegal substance abuse was calculated to be nearly 100 billion dollars [taken from the National Institute on Drug Abuse website; www.nida.nih.gov, 2002], reflecting a 50% increase above the estimate from 1985. One of the primary contributors to this expansion in drug-related expenses was reported to be the continued cocaine epidemic. With respect to the health consequences of cocaine use, cocaine was the most frequently mentioned illicit substance in drug-related emergency room visits for the year 2000 [3] . Additionally, in 1995, individuals seeking treatment for cocaine dependence comprised the largest number of admissions (38.3% of 1.9 million) to publicly funded substance abuse treatment facilities [ have relied primarily on psychosocial and rehabilitation approaches, which have long-term success in only a limited population of users. It is thought that the addition of a drug therapy to these behavioral treatments is necessary to increase the success rate for treatment of cocaine abuse and dependence [4] .
Several strategies have been attempted in the search for pharmacological adjuncts for the treatment of drug addiction. For example, in opiate abusers receptor-selective antagonists such as naltrexone have been administered in an effort to block the acute effects of the drug. In individuals with alcoholism, aversion therapy with disulfiram (Antabuse), an irreversible inhibitor of hepatic aldehyde dehydrogenase, has been used to punish drug-taking behavior. Ingestion of alcohol in the presence of disulfiram results in elevated levels of acetaldehyde causing nausea and other aversive symptoms. Another approach has been to use drugs with a similar mechanism of action to the drug of abuse, also known as agonist substitution therapy, which is the focus of this review. Agonist substitution therapy, such as methadone for heroin addiction and the various nicotine delivery systems for cigarette smokers, has proved beneficial for users seeking treatment. Success in these treatment groups has provided the impetus for the investigation of drugs that share pharmacological properties with cocaine [5] as one of the strategies for developing an effective pharmacotherapy for cocaine addiction.
Research in animals and humans has indicated that the behavioral effects of cocaine are primarily a result of its actions at the monoamine transporters. Cocaine binds to the dopamine (DA), serotonin (5-HT) and norepinephrine (NE) transporters with approximately equal affinity, preventing the reuptake of these monoamines. While it appears that the majority of the behavioral pharmacology of cocaine can be attributed to its blockade of the dopamine transporter (DAT), there is evidence for the involvement of serotonin and norepinephrine transporter (5-HTT and NET, respectively) inhibition as well. For example, nearly a quarter of a century's worth of research has demonstrated that increased synaptic DA mediates the reinforcing effects of cocaine and other psychostimulants [6, 7] . However, there are data suggesting that modulation of central 5-HT and NE systems can also influence cocaine's reinforcing effects, although to a lesser extent [8, 9, 10, 11] . It has been proposed that an ideal therapy should prevent any physiologically-based abstinence symptoms, including cocaine craving, normalize physiological functions disrupted by drug use and be targeted to a specific site of action that has been affected by the drug [4] . Drugs that act in a manner similar to cocaine fulfill the last of these criteria, and a number of drugs that act either directly or indirectly at these monoamine systems are being investigated for their effects in treatment outcomes related to the remaining guidelines.
In an effort to understand the neurobiological mechanisms of drug addiction, animal models are used as an experimental preparation to study the human condition. With animal models of any human condition, it is assumed that there are physiological and behavioral similarities between humans and laboratory animals that would allow for extrapolations to be made. There are three general categories of animal models of human diseases: predictive, isomorphic and homologous. Predictive animal models do not resemble the human condition in terms of etiology or symptoms, but the results are predictive of clinical outcome. Animal models that are considered isomorphic resemble the symptoms and clinical outcome of the human condition, but are artificially produced. In a homologous model, the disease state in animals emulates the human disorder in its etiology, symptoms and prognosis. The drug self-administration (SA) paradigm is based on principles of operant conditioning [12] and in the majority of studies reviewed here, is an example of an isomorphic model. The conditioned place preference (CPP) paradigm is based on the principles of Pavlovian conditioning and is an example of a predictive model. Both paradigms have provided valuable information regarding the abuse liability of drugs in humans [13, 14, 15] . One purpose of the present article was to extend these findings by determining if there is concordance between data from animals and humans concerning the abuse liability of monoamine agonists tested as substitution therapies for cocaine abuse and dependence. In this review, animal studies that have assessed the reinforcing (from SA studies) and rewarding (from CPP studies) effects of these drugs were compared to the actual prevalence of their use and potential for abuse in humans.
There is currently a disagreement with respect to the factors that control the initiation and maintenance of drug use. There are those who place more importance on the alleviation of a dysphoric state (negative reinforcement), due to either a pre-existing condition or abstinence from drug use, while others emphasize the positive reinforcing or appetitive properties of drugs [16] . Nevertheless, it is likely that both the positive effects as well as the abatement of some form of negative affect are involved in continued drug use. It could therefore be hypothesized that drugs that function as reinforcers (either through positive or negative mechanisms) or as appetitive stimuli in animal models may substitute for the primary drug of abuse in humans, acting as an effective agonist therapy. The second intent of this review, then, was to determine if the results from these preclinical abuse liability assessments of monoamine agonists were also predictive of their therapeutic efficacy in cocaine abuse and dependence. To that end, in addition to the conclusions that can be drawn from SA and CPP studies regarding the abuse potential of a given drug, it is possible that the results from those experiments may provide information on the use of that drug as a agonist medication for cocaine addiction. It should be emphasized that the preclinical studies reviewed here all involve assessment of abuse liability rather than examining the effects of drug pretreatments on cocaine self-administration. There is a wealth of studies showing that monoamine agonists and antagonists can alter cocaine self-administration and the reader is directed to Mello and Negus [17] for a review of the methodology and results from these studies. As noted above, despite a variety of pharmacological approaches to treat cocaine abuse and dependence, none have proven widely or consistently efficacious. However, there have been positive reports in controlled clinical trials and reports of success in limited patient populations with some of the agonist drugs that act at central monoamine systems. Therefore, the results from clinical trials with monoamine agonists were collected in an attempt to determine if any of the drugs (or classes of drugs) tested appeared more efficacious at treating cocaine abuse and dependence. These consolidated results were then compared to the data generated in animal models.
II. SELECTED DRUGS
Fourteen drugs with a primary mechanism of action at dopaminergic, serotonergic or noradrenergic central systems were identified that had been evaluated as potential treatments for cocaine abuse and dependence and had also been tested in animal models of abuse liability. Data regarding abuse liability in humans was found for 11 of the 14 drugs; it was assumed that the remaining 3 drugs had little or no abuse liability due to the absence of epidemiological or case report data concerning their misuse. Drugs with a dopaminergic mechanism of action included the DA precursor, l-dopa (Sinemet), the monoamine oxidase type B isozyme (MAO B ) inhibitor, l-deprenyl (Selegiline; Eldepryl), the DA-releasing agents, amantadine (Symmetrel), diethylpropion (Dospan, Tenuate) and damphetamine (Adderal, Dexedrine), the DAT inhibitors, bupropion (Wellbutrin, Zyban), mazindol (Sanorex) and methylphenidate (Ritalin), and the DA D 2 agonist, bromocriptine (Parlodel). The drugs acting at the serotonergic system included the 5-HT 1A partial agonists, buspirone (Buspar) and gepirone and the 5-HTT inhibitors, fluoxetine (Prozac) and imipramine (Tofranil). The only noradrenergic drug that met the search criteria was the tricyclic NET blocker desipramine (Norpromin).
III. DESCRIPTION OF COMPARISONS BETWEEN CLINICAL AND PRECLINICAL DATA

III.A. Abuse Liability Assessment in Laboratory Animals
III.A.1. Overview
In this review, results from studies that used drug selfadministration (SA) and conditioned place preference (CPP) methodologies were collected for comparison with data concerning the abuse liability of these drugs in humans and their efficacy as therapeutics for cocaine addiction. Methods that have been used to assess the pharmacological properties of drugs relevant to their abuse have also included measures of pharmacological equivalence, tolerance, the capacity for physical dependence, toxicity, performance impairment and the discriminative stimulus effects [18] . In particular, drug discrimination studies have frequently been used as a predictor of abuse potential. However, while this procedure is useful in classifying drugs according to their pharmacological profile, it is unclear to what extent the interoceptive cue produced by a drug is related to its abuse liability [19] , and so was not included in this review. None of these measures alone is likely to be sufficient to fully describe the abuse potential of a drug. Furthermore, there are a number of non-pharmacological factors, such as chemical properties of the drug, marketing, sociocultural and other chance factors that can contribute to the likelihood that a drug will be abused [18] . Nevertheless, results from SA and CPP studies in experimental animals have proven to be valid predictors of the likelihood of recreational use for many drugs and were therefore chosen as a preclinical measure of abuse liability for the purposes of this review. A summary of the SA and CPP studies that evaluated the abuse liability of the monoamine agonists listed above is shown in Table 1 .
III.A.2. Self-Administration
Positive reinforcement is defined as the ability of a stimulus (e.g., a drug) to increase the likelihood of the behavior that immediately preceded its presentation [20] . In a commonly used type of drug self-administration paradigm, responses on an operant manipulandum (e.g., a lever) are initially maintained by the delivery of a stimulus having known reinforcing effects (e.g., cocaine) under any of a number of schedules of reinforcement. A test drug can then be substituted for the stimulus that previously maintained responding in order to assess the reinforcing effects, if any, of the test drug. The drug is considered reinforcing if it maintains significantly greater levels of responding compared to when the drug vehicle was substituted. In addition to simple substitution studies, the reinforcing effects of drugs can be evaluated using choice procedures, in which two drugs, two doses of a drug, or a drug and a non-drug reinforcer are made available for self-administration as alternatives to each other. In the studies reviewed here, both substitution and choice procedures were used, and responding was maintained by fixed-ratio (FR), fixedinterval (FI) or progressive-ratio (PR) schedules of drug delivery. Under the FI and FR schedules, reinforcer delivery is contingent upon the completion of an operant response following a particular time interval (FI) or a set number of responses (FR). For the PR schedule, the number of required responses increases for successive reinforcer delivery, either across or within the experimental session. For additional information on self-administration methodologies, see reviews by [21, 22, 23] .
III.A.3. Conditioned Place Preference
While the SA paradigm is used as a measure of the reinforcing effects of drugs, CPP can be said to assess the rewarding properties of drugs. The term rewarding refers to the appetitive nature of a drug stimulus as opposed to the ability of these drugs to increase the probability of a given behavior, as it is unclear what class of behaviors are being strengthened [24] . Under the conditions of the CPP paradigm, a stimulus is repeatedly paired with one of two distinct environmental contexts. Following this contextual conditioning, the animals are then given unrestricted access in a drug-free state, and the relative time spent in each environmental context is measured. A variety of stimuli have been shown to condition a place preference, including many drugs commonly abused by humans [15] . In a recent review of CPP, Bardo and Bevins [24] noted that while it appears that CPP and SA are not isomorphic measures of drug reward, they may provide complementary information with respect to drug-taking behavior. For example, lysergic acid diethylamide (LSD), a hallucinogen well known for its recreational use in humans, does not function as a reinforcer in animals [W. E. Fantegrossi, personal communication, 2002 ] but does condition a place preference [25] . A full discussion of the basis for conditioned place preference and a comparison with the self-administration procedure are beyond the scope of this review, however, the authors direct the reader to several thorough discussions on these topics [24, 26, 15] .
III.A.4. Selection Method
PubMed (www.pubmed.gov), a MEDLINE search engine, and Scirus (www.scirus.com), a MEDLINE and WorldWideWeb search engine, were used to compile references for this review. Searches were conducted using the following terms: self-administration, reinforce (-ing, -ment), rewarding, conditioned place preference, abuse liability, abuse potential and were limited to publications in English that contained data from animal subjects. The publications located with the initial search were then scanned for further related references. Although the focus of this review is related to candidate treatments for cocaine abuse and dependence, studies that used d-amphetamine as a reference or baseline drug instead of cocaine were included because of the similar behavioral profile of these two psychostimulants.
III.B. Abuse Liability Assessment in Humans
III.B.1. Overview
Different sources of data were combined in order to estimate the abuse liability of drugs that have been tested as pharmacotherapies for cocaine addiction. These sources consisted of data related to the potential of these drugs to be abused as well as data regarding the prevalence of their abuse and are summarized in Table 2 . Studies that were designed specifically to evaluate the propensity of these [114] for a detailed listing of the animal studies that have investigated the abuse liability of methylphenidate drugs to be misused were found for 6 of the 14 reviewed drugs. Of the various methods that have been used to ascertain abuse liability in humans, procedures that assessed the reinforcing effects and subjective effects of the drugs reviewed here will be discussed. There is a brief description of these methods below; however, there have been several informative reviews published on the use of these measures for the assessment of abuse liability [27, 28, 29] .
III.B.2. Self-Administration
Drug abuse has been defined, in part, as the use of a drug for non-medical reasons. Thus, the ability of a drug to maintain self-administration when available under controlled experimental conditions is likely the best predictor of its abuse liability. Self-administration studies in humans are typically carried out using either free-access conditions or choice procedures, and often utilize response contingencies according to the schedules of reinforcement described above. Additionally, the ability of the drug to function as a reinforcer is similarly defined as the level of drug intake during active drug versus placebo conditions. These types of studies have demonstrated that drugs used for recreational purposes from a variety of pharmacological classes will maintain self-administration under controlled laboratory conditions [29] .
III.B.3. Subjective Effects
The evaluation of the subjective effects of a drug has proven to be an effective means of predicting its abuse liability [29] . In these studies, the subjective response to drug administration is measured and compared to either placebo or the subjective state prior to drug administration. These results can then be directly compared to the subjective response to known drugs of abuse. A short description of the instruments used to assess the subjective effects in the papers surveyed for this review is given below.
The Addiction Research Center Inventory (ARCI) is a true or false questionnaire that is subdivided along 4 dimensions of subjective experience based on the effects of specific drugs or classes of drugs. The morphine benzedrine group (MBG) scale is described as being a measure of the euphoric properties of a drug. The pentobarbital, chlorpromazine and alcohol group (PCAG) scale is considered to be a measure of sedation. The lysergic acid diethylamine (LSD) scale is considered a measure of somatic and dysphoric effects of a drug. Finally, the benzedrine group scale and d-amphetamine (BG-A) scale are used as a measure of stimulant effects. There are several different variants of the ARCI that have been used since its initial development, including an abbreviated "ARCI short-form", a version that contains the addition of the amphetamine (A) scale and a modified version that used a 7-point rating scale for each item instead of true/false questions.
The Single-Dose Questionnaire (SDQ) was designed to measure the subjective response to a drug in experienced users. This questionnaire is used to determine the presence or absence of an active drug, identify it, report on any symptoms and rate the drug in terms of "liking".
The Profile of Mood States (POMS) is a questionnaire which requires the subject to rate their current mood state according to a list of adjectives that can be ranked on a 5-point scale ranging from "not at all" to "extremely". The 65-adjective version has been divided into 6 mood clusters: anxiety, depression, anger, fatigue, vigor and confusion. A 72-item version has also been developed that is more sensitive to stimulant rated effects.
In addition to these standardized questionnaires, some investigators have chosen to design their own instruments for measuring subjective effects. These novel questionnaires consist of a number of adjectives or phrases designed to describe the subject's present affective state and are usually rated using ordinal scales such as Visual Analog Scales (VAS) and Likert Scales, interval scales (e.g., 1-10), or some form of a nominal ranking (e.g., yes/no, true/false). Visual Analog Scales are 100-mm lines anchored at both ends by opposing labels such as "not at all" and "extremely". Likert scales are, in general, 5-or 7-point scales consisting of labels ranging from "disagree" to "agree". For these scales, subjects are instructed to either place a mark along the continuum of the line (VAS) or select an answer (Likert, interval, nominal) indicating how they feel regarding that particular descriptor.
Several of the drugs reviewed here have not been evaluated for abuse potential under experimental conditions specifically designed to assess subjective effects. However, various studies were found that described one or more subjective effects of these drugs associated with their use. The publications that contained subjective reports of euphoria were included in this review in an effort to present all of the available data regarding the abuse potential of the drugs that have been investigated as pharmacotherapies for cocaine addiction. The inclusion of these publications in this review, we believe, is justifiable based on the concordance that has been established between subjective reports of euphoria and the likelihood that a drug will be abused [30] .
III.B.4. Epidemiological Data
The incidence of misuse of the monoamine agonist drugs presented here was also used as an indicator of abuse liability. Data concerning the prevalence of the use of these drugs were taken from primarily two sources. The first source was in the form of case reports submitted by physicians for publication that detailed the illicit use of a prescribed drug in one or more patients. While relatively unstructured, the importance of case reports in detecting abuse liability has been emphasized previously [31] , and were therefore included in this review. Additional information was taken from the epidemiological data collected by the Drug Abuse Warning Network (DAWN) for 1997 and the National Household Survey on Drug Abuse (NHSDA) for 1999. The DAWN provides estimates on the number of emergency room admissions for problems induced by or related to the non-medical use of a legal drug or any use of an illegal drug. These estimates include all persons over the age of six years and are based on a representative sample of short-stay, general hospitals from major cities around the U.S. The NHSDA collects data regarding the prevalence and correlates of drug use in the U.S. in the civilian, non-institutionalized population aged 12 years and older. There have been criticisms of the reliability and validity of the data collected by these methods [32, 33] . However, because those data were included here, in part, with several other sources, and were used to determine if a particular drug had any incidence of use and not to characterize the extent of abuse solely on these reports, the authors refer to these statistics, but recognize their limitations. In combination with the studies that assessed the abuse liability of the drugs presented here, these data on the prevalence of use were used as the basis against which the findings from preclinical studies could be compared.
III.B.5. Selection Method
In collecting references related to the abuse liability in humans of monoamine agonist drugs that have been tested in clinical trials for cocaine addiction, the scientific search engines, PubMed and Scirus were used. A search for the following terms limited to publications in English and in humans was conducted: self-administration, reinforce (-er, -ment), abuse, misuse, euphoria and subjective effects. The publications located with the initial search were then scanned for further related references. In addition, raw data from the DAWN [34] and NHSDA [35] databases were taken from the SAMHSA website (www.samhsa.gov/oas/oas.html). As described above for the preclinical studies, although the focus of this review is related to candidate treatments for cocaine abuse and dependence, studies that used damphetamine as a reference or baseline drug instead of cocaine were included because of the similar behavioral profile of these two psychostimulants.
III.C. Treatment Efficacy for Cocaine Abuse and Dependence
III.C.1. Overview
Data from preclinical models of drug abuse were also compared to the results from publications that described the efficacy of monoamine agonists as treatments for cocaine abuse and dependence. Table 3 presents a summary of the studies that were identified as having assessed the therapeutic effects of these drugs. The studies that are reviewed here include clinical trials, case reports and experiments in which the effects of cocaine were tested in combination with a test drug. The latter studies typically enlisted cocaine users that were not seeking treatment, whereas the former were conducted in patients enrolled in treatment programs or seeking the assistance of a physician. These studies differed across a number of variables, including patient population, trial design, (controlled or open-label), treatment duration, medication dose and setting (inpatient or outpatient). The primary dependent measures reported in these publications reflected a range of treatment outcomes and are summarized briefly below. Specific dependent measures varied across studies, but for the purpose of this review were grouped into several generalized categories: treatment retention, cocaine use, abstinence symptoms (including craving), global assessment, self-report and changes in the effects of cocaine following use or experimental administration. For this review, a drug was considered to have therapeutic efficacy if there was a significant beneficial change in one or more of the treatment outcomes for a given study, with minimal side effects. The instruments used to measure these treatment outcomes consisted of standardized, validated scales as well as novel devices created specifically for that particular study. A full listing and description of the instruments used in each study is too extensive to be covered here, however, several of the more traditional and often-used ones are mentioned as examples.
III.C.2. Treatment Outcome
Retention was considered the continued compliance and attendance of the patients in the different treatment groups. Descriptive statistics were generally used to describe patient retention in the study. Changes in cocaine use were detected with plasma or urine screening, self-reported use, and selfreported dollar amount spent on cocaine over a given period of time. Plasma and urine were typically screened for benzoylecgonine (BE), the primary metabolite of cocaine. Cocaine use was reported by subjects using scales such as the Quantative Cocaine Weekly Inventory to evaluate use in terms of the frequency of use, the quantity of drug used and the amount of money spent on purchasing cocaine. Abstinence symptoms include depression, anxiety, fatigue, anger or hostility and craving for cocaine, although emergence of these symptoms appears to depend on the severity of use as well as the treatment setting in which abstinence is initiated [36, 37, 38] . Alterations in the magnitude or the presence of these symptoms was assessed with a wide variety of subject-and observer-rated scales that were specific for a particular dimension of cocaine abstinence or encompassed a range of symptoms. For In addition, diagnostic instruments were sometimes used that made a global evaluation of changes in abstinence symptoms. These included the POMS, ARCI, the Global Assessment Scale (GAS), the Brief Psychiatric Rating Scale (BPRS) and the Symptom Checklist-90 (SLC-90). Changes in the subjective response to cocaine when administered in combination with the candidate medication were typically assessed using the standard approaches described in the section on the abuse liability of monoamine agonists in humans, in addition to a number of novel instruments. Although the physiological interaction between the agonist treatment and cocaine were also investigated in the cocaine challenge studies, those data were not presented here. Finally, several scales have been developed that measure more than one type of treatment outcome with a single instrument, such as the Yale Quantitative Cocaine Inventory (QCI) that evaluates craving, cocaine use and the quality of the cocaine high while receiving medication.
III.C.3. Selection Method
References related to the efficacy of monoamine agonists at treating cocaine abuse and dependence were collected using the scientific search engines, PubMed and Scirus. A search, limited to studies in humans and published in English, was conducted using combinations of the terms: cocaine, abuse, addiction, dependence, treatment, agonist, (pharmaco-) therapy and substitution. The publications located with the initial search were then scanned for further related references.
IV. SUMMARY OF COMPARISONS BETWEEN PRECLINICAL AND CLINICAL DATA
IV.A. Preface
The following comparisons between the preclinical and clinical data collected are not meant to be complete discussions of all of the data concerning the abuse liability and therapeutic efficacy of these monoamine agonists. Instead, these brief summaries, in conjunction with the associated tables, were intended to provide a concise synopsis that related the overall findings from the available studies in an effort to identify the predictive validity, if any, of the animal models that are discussed here. It is likely that any relationship that existed between the clinical and preclinical studies would be imperfect. In fact, this was expected, considering the many other factors that can contribute to the abuse liability or therapeutic efficacy of a drug in an individual. The intent, then, was to discern trends in the data suggesting that the results from animal studies that measured the reinforcing and conditioned rewarding effects of drugs were predictive of the abuse liability of those drugs in humans or their efficacy as medications for cocaine addiction. Based on previous reports, it was expected that the correspondence between the results from CPP and SA studies in animals and the abuse liability of drugs in humans would extend to the drugs reviewed here. To our knowledge, however, a comparison between the reinforcing and rewarding effects of drugs tested as pharmacotherapies for cocaine abuse and dependence and their therapeutic efficacy has never been made. As noted in the Introduction, it could be hypothesized that drugs that function as reinforcers or as appetitive stimuli in animals may act as an effective agonist therapy in humans by substituting for the primary drug of abuse. Should this be the case, the results from CPP and SA experiments may provide predictive information on the use of that drug as a medication for cocaine addiction in addition to its potential for abuse.
IV.B. Dopaminergic Drugs
IV.B.1. DA Precursors
IV.B.1.a. l-Dopa
The catecholamine precursor, l-dihydroxyphenlalanine (ldopa; Sinemet), is prescribed in Parkinson's disease patients in an effort to increase cerebral concentrations of DA. In addition to its well-documented therapeutic effects, l-dopa has also been reported to produce euphoria in Parkinson's patients [39, 40, 41, 42] (Table 2) . These findings are consistent with the results from a study by Katajamaki et al. [43] using conditioned place preference ( Table 1) . The reports of euphoria in Parkinsonian patients are from a relatively homogenous population, however, and limit the conclusions that can be drawn about the abuse liability of ldopa in the general public. On the other hand, the abuse of ldopa in this population illustrates how nonpharmacological factors such as availability can influence the extent of abuse. The rewarding effects of l-dopa demonstrated in the study by Katajamaki and colleagues, however, were not predictive of the clinical efficacy of l-dopa as a treatment for cocaine abuse and dependence. Initial attempts at use with l-dopa as a substitution therapy in open trials appeared promising [44, 45] , but a controlled inpatient study in 30 patients with primary cocaine dependence indicated that l-dopa was not significantly more effective than placebo [46] (Table 3) .
IV.B.2. MAO A Inhibitors
IV.B.2.a. l-Deprenyl
The selective and irreversible monoamine oxidase type B isozyme (MAO B ) inhibitor, l-deprenyl (Selegiline; Eldepryl), is also prescribed for Parkinson's disease, and has been evaluated as a treatment for major depression and Alzheimer's disease [47, 48] . There is some contention about the mechanism by which l-deprenyl produces its therapeutic effects [49] . Nonetheless, it appears to indirectly increase synaptic DA levels and for this reason l-deprenyl has been evaluated for its potential for abuse and as a treatment for cocaine addiction. When substituted for cocaine in rhesus monkeys [50] , l-deprenyl did not function as a reinforcer, but facilitated the acquisition of conditioned place preference when administered to mice [51] (Table 1) . These inconsistent results concerning the abuse liability of ldeprenyl may reflect the assertion that these two procedures are measures of fundamentally different behavioral processes [24] . Perhaps in keeping with the animal data, there are case reports describing "arousal" and "mood elevation" as a result of l-deprenyl treatment in Parkinson's patients [52, 53] ( Table 2) . However, the general consensus in the literature is that l-deprenyl has little to no abuse liability [54, 55] . Three studies have been published regarding the effects of ldeprenyl on intravenous cocaine challenge ( Table 3 ). In two of these cocaine challenge experiments, l-deprenyl decreased the subjective response of "high" [56, 57] and "stimulated" [57] following cocaine administration, at a dose of 10 mg per day. In contrast, another study showed no effect of ldeprenyl on the physiological or subjective effects of experimental cocaine administration [58] . Currently, the National Institute on Drug Abuse is undertaking a multi-site controlled clinical trial to evaluate the efficacy of l-deprenyl, which will hopefully clarify the potential of this drug as a pharmacotherapy for cocaine abuse and dependence.
IV.B.3. DA Releasers
IV.B.3.a. d-Amphetamine
In addition to its effects on DA reuptake and release, damphetamine (Adderal, Dexedrine) is also a potent indirect agonist of 5-HT and NE receptors. The ability of damphetamine to maintain behavior contingent upon its presentation has been well documented in animals and humans. Furthermore, it is often used as a standard against which the potential for misuse of a given drug can be compared. Because of its similar behavioral effects to cocaine, but its prolonged duration of action, d-amphetamine is being considered as an agonist substitution therapy. A recent report by Grabowski and colleagues [59] demonstrated a significant difference in benzoylecgoninepositive urines following treatment with a sustained-release preparation of d-amphetamine compared to placebo in cocaine-dependent subjects ( Table 3) . One issue that has precluded other controlled clinical studies with damphetamine is its potential for abuse. The limited clinical data with d-amphetamine, however, support the proof of concept for agonist therapies for cocaine addiction.
IV.B.3.b. Amantadine
Originally prescribed for its antiviral activity in treating influenza A, amantadine is also indicated for Parkinson's disease. Although the mechanism of amantadine's therapeutic effects for Parkinson's is not clear, it has been attributed to either its ability to alter DA release or to its anticholinergic effects. Amantadine does appear to have a significant dopaminergic action, however, like several other DA agonists, amantadine shared discriminative stimulus effects with d-amphetamine in rats [60] . Of the 9 pharmacological agents with a dopaminergic mechanism of action, only the DA-releaser amantadine (Symmetrel) showed no indication of abuse potential, which may be attributible to its other pharmacological actions. When made available for self-administration in baboons, a range of amantadine doses did not maintain responding significantly greater than vehicle-maintained responding [61] (Table 1) . However, like some of the other drugs discussed here, this drug was only tested in a single study, therefore it is difficult to draw definitive conclusions regarding its abuse liability. Consistent with the preclinical data, there were no incidences of amantadine abuse found on Medline or Cirius, and no mention of the presence of amantadine during emergency room admissions as reported by the DAWN [34] . Because of its frequent clinical use, it seems likely that if amantadine had a significant propensity for misuse, there would be documented cases available. In addition to its other clinical uses, amantadine has been evaluated in numerous controlled clinical trials as a cocaine pharmacotherapy [62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74] , with equivocal results overall ( Table 3) .
IV.B.3.c. Diethylpropion
In contrast with the minimal abuse capacity of amantadine, it is evident that the anorectic diethylpropion (Dospan, Tenuate), which also releases DA from synaptic terminals, has the potential for misuse. Several preclinical studies have documented the reinforcing [75, 76, 77, 78, 79] and conditioned rewarding effects [80] of this drug ( Table  1 ). In a study by Jasinski et al. [81] , diethylpropion was shown to have subjective effects similar to d-amphetamine ( Table 2 ). In addition, it was reportedly misused by 0.1% of the population surveyed for the NHSDA [35] , rates comparable to the 0.2 % that purportedly used damphetamine for non-medical purposes. Furthermore, there are case reports documenting the misuse of diethylpropion [82, 83] (Table 2 ). Alim and colleagues [84, 85] investigated the efficacy of diethylpropion under inpatient conditions in cocaine users seeking treatment ( Table 3) .
In an initial openlabel, dose run-up study, diethylpropion appeared promising; administration of increasing doses affected subjective ratings of craving and mood state [84] . However, a controlled study did not confirm a significant benefit of diethylpropion compared to placebo [85] . It appears that the observed therapeutic effects in the open label study were not the result of diethylpropion treatment, but were instead consistent with a reduction in craving and improvement in mood states that are observed in cocaine users following hospitalization [38] . As it pertains to the strategy of substitution therapy, diethylpropion, like l-dopa, has abuse liability but possessed equivocal therapeutic efficacy as a cocaine pharmacotherapy.
IV.B.4. DAT Inhibitors
IV.B.4.a. Bupropion
A positive relationship has been demonstrated between the behavioral potency of psychostimulants to maintain selfadministration in laboratory animals and their affinity for DAT [86, 87, 88] . In keeping with that relationship, the DAT blocker bupropion (Wellbutrin, Zyban) functions as a reinforcer when made available for self-administration [86, 89, 90] and has also been shown to facilitate the conditioning of place preference [91] (Table 1) . In humans, the potential for abuse is less clear ( Table 2 ). In a recent study by Cousins et al. [92] , bupropion was reported to produce euphoria when tested for its effects on cigarette smoking. Additionally, a recent case report by McCormick [93] described the abuse of bupropion by a teenager. Data from the NHSDA [35] revealed that 0.2 % of those surveyed had misused bupropion, similar to the percentage of damphetamine rates of use. Furthermore, it is the author's (J. A. L.) personal experience that some individuals prescribed Zyban for the purposes of smoking cessation will crush and snort it for its euphoric and stimulant effects. Nevertheless, it is evident from a number of studies explicitly designed to assess the behavioral effects of bupropion that it does not share subjective stimulus properties with d-amphetamine [94, 95, 96, 97, 98] , which implies that this DAT inhibitor does not have robust psychomotorstimulant effects. In addition, bupropion does not have robust therapeutic effects in addicted cocaine users. As an agonist treatment, bupropion appeared useful in an initial open-label study [99] , however further controlled examination of bupropion's therapeutic effects produced negative results [100, 101, 102] ( Table 3) .
IV.B.4.b. Mazindol
Like bupropion, mazindol (Sanorex) is an inhibitor of DA reuptake that also does not share subjective effects with d-amphetamine, but instead is described as dysphoric by human subjects [103, 104] (Table 2 ). This is one of the few instances where the preclinical findings ( Table 1) that mazindol functions as a reinforcer [86, 105, 106] and as an appetitive stimulus [107] do not coincide well with the human data. It should be noted however, that in the selfadministration studies mazindol maintained responding in only half of the squirrel monkeys tested [86] . Further, mazindol maintained lower break-points than cocaine under a progressive-ratio schedule [105] , indicative of lower reinforcing efficacy. These data would suggest that mazindol may have weak reinforcing effects, consistent with the results from studies in humans. Clinically, mazindol did not alter the magnitude or the profile of the subjective response to cocaine [108] , had toxic side-effects [109] and was not shown to be effective in 2 of 3 controlled studies for cocaine addiction [110, 111, 112] (Table 3) .
IV.B.4.c. Methylphenidate
Methylphenidate (Ritalin) is currently, and most frequently prescribed for the treatment of attention deficit and hyperactivity disorder (ADHD). Neurochemically, methylphenidate is similar to cocaine; its affinity at DAT and onset of action are nearly identical to cocaine, but methylphenidate dissociates from DAT at a much slower rate [113] . For these reasons, methylphenidate would appear to be an appealing candidate as a cocaine agonist therapy. However, for these same reasons, there is also some concern regarding its potential for diverted use. A comprehensive review of the abuse liability of methylphenidate was published recently by Kollins et al. [114] . In this review, the authors presented abuse liability data in animals and humans as well as data regarding the actual prevalence of methylphenidate misuse and abuse. From their survey of the literature, Kollins and colleagues concluded that methylphenidate "is not benign with respect to abuse potential". In humans, methylphenidate has been shown to have amphetamine-like subjective effects, including euphoria, and is reported to have reinforcing effects under controlled laboratory conditions, consistent with the outcome from self-administration and CPP studies [114] . Initial studies with methylphenidate as a candidate medication for cocaine abuse and dependence appeared promising, particularly in patients with pre-existing ADHD [115, 116] . However, controlled studies revealed that methylphenidate was not widely successful [117, 118, 119] and has even been reported to exacerbate craving in abstinent cocaine users [120] (Table 3) .
IV.B.5. DA D 2 Receptor Agonists
IV.B.5.a. Bromocriptine
Initial interest in the use of bromocriptine (Parlodel) as a therapeutic for cocaine addiction was in response to the DA depletion hypothesis [121] . According to this theory, craving and the negative mood states associated with discontinued cocaine use is the result of a depletion of DA concentrations in the brain due to chronic reuptake inhibition, and thus less neuronal DA available for release. Bromocriptine, a DA D 2 receptor agonist, was initially hypothesized to be beneficial with the thought that it would stimulate post-synaptic DA receptors in place of the depleted dopamine. The DA D 2 receptor has been actively researched for its involvement in psychostimulant abuse and is clearly involved in mediating the effects of these drugs. For example, dopamine D 2 agonists themselves are self-administered by laboratory animals [e.g., 122, 123] . Furthermore, DA D 2 -selective agonists shift the cocaine self-administration dose-effect curve leftward, consistent with an enhancement of the reinforcing effects of cocaine [e.g., 122, 123] , while DA D 2 antagonists decrease the reinforcing effects of cocaine [e.g., 124, 125] . Like other DA D 2 agonists, bromocriptine functions as a reinforcer when made available for selfadministration to rats and rhesus monkeys [126, 127] , and induces CPP in rats [128] ( Table 1) . There have not been any studies specifically examining the abuse liability of bromocriptine in humans. A thorough search of the literature revealed a single report of bromocriptine abuse [129] , suggesting that while this drug can have reinforcing effects in humans, in agreement with the results from animal studies, the prevalence of its abuse is low ( Table 2 ). There has been extensive research regarding the use of bromocriptine as a treatment for cocaine use and dependence, including numerous controlled clinical trials [130, 131, 132, 133, 134, 64, 135, 136, 72] , as well as experiments designed to assess its effects when given in combination with cocaine [137, 138, 139] (Table 3 ). While many of these studies appeared encouraging, bromocriptine has not proven to be consistently efficacious at treating cocaine abuse and dependence. Moreover, the incidence of undesirable side effects may have limited bromocriptine use, despite any therapeutic advantanges.
IV.C. Noradrenergic Drugs
IV.C.1. NET Inhibitors
IV.C.1.a. Desipramine
The abuse potential of the tricyclic antidepressant, desipramine (Norpromin), has been tested preclinically in only a single study. In that study, Papp [140] found that desipramine did not condition a place preference when administered in rats ( Table 1) . Consistent with this limited animal data, there were no published incidences of diverted desipramine use that were found. There were reports from the DAWN [34] network of 401 mentions of desipramine in emergency room admissions, however, this comprised only 0.1% of the total drug-related ER admissions. There have been a large number of clinical trials that have assessed the potential of desipramine as an adjunct in cocaine users seeking treatment [141, 142, 143, 144, 145, 146, 147, 148, 69, 149, 70, 150, 71, 73, 151, 152] . Like all of the drugs that have been tested for this purpose, there have been positive and negative results. Desipramine, though, has proven successful in a number of trials with respect to at least one of the treatment outcome variables (Table 3) . Moreover, a meta-analysis by Levin and Lehman [153] , showed that desipramine was significantly effective at promoting abstinence from cocaine use although it had no effect on a number of other dependent measures. As it pertains to substitution therapy, the preclinical indication of little to no abuse liability is in contrast to desipramine's (limited) efficacy as a cocaine pharmacotherapy. Buspirone (Buspar) is an anxiolytic drug that differs from traditional anxiolytics in that its mechanism of action is thought to be via an interaction with the 5-HT 1A receptor subtype as opposed to the benzodiazepine binding site of the ionotropic gamma-aminobutyric acid (GABA A ) receptor. Because of the propensity for misuse of benzodiazepine anxiolytics, buspirone has been thoroughly evaluated in animals and humans for its potential for abuse. Buspirone does not maintain self-administration when made available to rhesus monkeys or baboons under various schedule conditions [154, 155] , whereas the results from CPP experiments in rodents have been inconsistent (Table 1) . Studies by Ali and Kelly [156] and Matsuzawa et al. [157] showed that buspirone was ineffective at conditioning place preference, while a study by Neisewander [158] demonstrated CPP following administration of buspirone. In yet another study, File [159] reported that buspirone was only partially effective at inducing CPP. Taken together, the preclinical experiments with buspirone suggest that abuse of this drug would be unlikely. Human studies with buspirone have assessed its behavioral effects in a variety of subject populations, including healthy individuals [160, 161] , recreational sedative users [162] , non-dependent multiple drug users [163] , alcoholics [164] and abstinent alcoholics [165] . The data concerning the abuse liability of buspirone in humans support the observations from animal research (Table 2) . Overall, buspirone has been shown to have sedative effects, but unlike the benzodiazepines, does not appear to have positive subjective effects and may result in dysphoric mood states at higher doses. A single study was found that had evaluated the therapeutic efficacy of buspirone in cocaine abstinence ( Table 3 ). In that study, Giannini and colleagues [166] reported that the buspironetreated cocaine users scored lower on the Brief Psychiatric Rating Scale compared to controls and while not significant, tended to have less benzoylecgonine-positive urines.
IV.D. Serotonergic drugs
IV.D.1.b. Gepirone
Assessments regarding the abuse liability of gepirone mirrored the findings with buspirone ( Table 1) . When available for self-administration in rhesus monkeys, gepirone did not maintain responding significantly greater than vehicle [167] . Further, gepirone administration conditioned a place preference under the identical experimental conditions that buspirone induced CPP [158] . While there were not any studies identified that directly assessed the likelihood of gepirone abuse in humans, Balster [167] judged the potential for diverted use to be low based on the data from its closelyrelated congener, buspirone ( Table 2) . In contrast to the positive results from the Giannini et al. [166] study with buspirone, gepirone treatment groups did not differ from placebo across a variety of outcome measures [168] (Table  3) . Buspirone, unlike gepirone, has actions as a DA antagonist, which may explain their differences in clinical efficacy, although additional studies will be required to reveal actual distinctions between these drugs.
IV.D.2. 5-HTT Inhibitors
IV.D.2.a. Fluoxetine
Suprisingly, there is very little preclinical data on the abuse liability of the widely prescribed selective serotonin reuptake inhibitor (SSRI), fluoxetine (Prozac). The only selfadministration data found were from a preliminary study in monkeys showing that fluoxetine did not function as a reinforcer [169] . Like buspirone, the conditioned rewarding effects of fluoxetine have not been consistent across experimental conditions ( Table 1) . Fluoxetine did not induce CPP in mice [170] , but did facilitate acquisition of CPP in rats in three other studies [171, 172, 173] . These results indicate that fluoxetine may have weak rewarding properties under some conditions. In support of this presumption, there have been a few reports of the misuse of fluoxetine taken both intranasally and intravenously [174, 175, 176] (Table  2) . Furthermore, the DAWN [34] reported that there were just over 10,000 fluoxetine mentions in drug-related ER admissions in 1997, approximately equivalent to the number of cases in which d-amphetamine was involved. However, given the freqency of its use as an antidepressant compared to the limited incidence of abuse in humans and the inconsistent findings from the animal studies, fluoxetine does not appear to be a drug that is likely to be abused to a large extent. Despite two open-label trials that indicated efficacy at decreasing cocaine use and craving [177, 178] and a controlled, challenge study that demonstrated a diminished subjective response to cocaine following fluoxetine administration [179] , controlled clinical trials in cocaine users seeking treatment have been unsuccessful [180, 181, 182, 183] (Table 3) .
IV.D.2.b. Imipramine
When the conditioned rewarding effects of imipramine (Tofranil) were evaluated, it did not produce CPP in rats [184, 140] and, in fact, conditioned a place aversion. Additionally, imipramine did not maintain selfadministration in baboons when substituted for cocaine [89] , a profile consistent with the findings from abuse liability evaluation of tricyclic antidepressants like desipramine ( Table 1) . The animal data are in agreement with the apparent low abuse liability of imipramine in humans. There were no reports of imipramine diversion found, although there was a small percentage (0.3%) of drug-related ER admissions in which imipramine was mentioned [34] . Clinical trials with imipramine have reported similar outcomes to studies investigating desipramine in that there were positive findings regarding some, but not all dependent measures of efficacy [185] (Table 3) .
V. SUMMARY AND CONCLUSIONS
V.A. Overview
One strategy for developing pharmacological treatments for cocaine addiction involves agonist substitution. This approach has proven relatively successful for heroin addiction with the use of methadone and cigarette smoking using nicotine delivery systems. The intent of this review was to present data from animal models that assessed the reinforcing and conditioned rewarding effects of the monoamine agonists that have been tried as replacement medications for cocaine addiction. Those data were then compared to the abuse liability of these drugs in humans and to their efficacy as therapeutics for treating cocaine abuse and dependence to determine if these animal models were predictive of their effects in humans. These comparisons were made because it has previously been reported that the variables affecting drug-taking behavior in animals and humans are similar, and that drugs used by humans are also typically self-administered in animals. It stands to reason that drugs that act in a manner similar to cocaine (i.e. monoamine agonists) may have abuse potential and therefore it is important to validate these models for their ability to estimate the abuse liability of drugs in humans. Furthermore, because the initiation and continued use of cocaine is thought to be due, in part, to its reinforcing and rewarding effects, these models may also provide predictive value with respect to their potential as substitution therapies. Fourteen drugs with a primary mechanism of action at either the DA, 5-HT or NE systems were identified that had been tested as potential treatments for cocaine addiction and had also been evaluated in either the self-administration or conditioned place preference paradigms in animals. From these comparisons, it was concluded that, in the majority of cases, the animal models were predictive of the abuse liability of these monoamine agonists in humans. There did not, however, appear to be a predictive relationship between the reinforcing and conditioned rewarding effects of these monoamine agonists and their ability to affect the desired treatment outcomes for cocaine addiction.
V.B. DA Involvement
In the animal studies presented here, each of the DAselective drugs tested in CPP (all except amantadine) appeared to possess appetitive stimulus properties and most of the DA-selective drugs made available for selfadministration (all except l-dopa) functioned as reinforcers. These findings are consistent with other studies demonstrating the reinforcing and rewarding properties of DA-selective drugs [186, 128, 187, 188, 189, 127] . In agreement with what has been reported previously [13, 14, 15] , there was a good concordance between the results from abuse liability assessments in laboratory animals and the potential for misuse or abuse in humans. Furthermore, of all the monoamine agonists reviewed, the DA-selective drugs also appeared to have the greatest potential for abuse. Administration of many of these drugs in humans resulted in reports of euphoria and subjective effects similar to damphetamine. Together, these data are in agreement with the extensive literature that implicates increased extracellular concentration of DA in the rewarding and reinforcing effects of drugs having psychomotor stimulant properties. In fact, it has been demonstrated that all drugs that are abused by humans elevate extracellular DA, although the mechanism by which this occurs differs across drugs [190] . The ability of dopaminergic drugs to function as reinforcers or as appetitive stimuli did not, however, appear to be predictive of their efficacy at treating cocaine abuse and dependence. Of the 50 peer-reviewed studies and case reports that evaluated DA-selective drugs for their efficacy as treatments for cocaine addiction, there was an approximately equal percentage of instances in which the therapeutic was deemed efficacious for at least one dependent measure compared to when there was no effect.
V.C. NE Involvement
The single drug acting on the central NE systems that met the selection criteria for this review was the tricyclic antidepressant, desipramine, which has a high affinity for NET. There has been a great deal of clinical research evaluating the therapeutic efficacy of desipramine in cocaine abuse and dependence, but very little data from human or animal research concerning the abuse liability of desipramine. While there is evidence that central noradrenergic systems contribute to the discriminative stimulus and subjective effects of psychostimulants [191, 192, 193] , the ability of NE to mediate reinforcing and rewarding effects is unclear. Although it is generally reported that NE has little involvement in these effects, there are data that both support and conflict with this supposition and are not sufficient to ascertain a definitive relationship. The estimation of desipramine's lack of abuse potential was consistent across animals and humans and is also in agreement with a prior study demonstrating that the NET inhibitor nisoxetine and the α 1 receptor agonist, methoxamine, did not maintain responding when made available for self-administration [194, 195] . In contrast, it is evident from preclinical and clinical data that the selective NE α 2 receptor agonist, clonidine has the potential for misuse [196, 197, 198] . Thus, it appears that the NE system may contribute to the reinforcing and rewarding effects of cocaine and other drugs, possibly via the NE α 2 receptor, although blockade of NET alone may not be sufficient to produce these effects. Further research is warranted to gain a better understanding of the behavioral effects of drugs mediated by NE. As a therapeutic, desipramine was reported as efficacious along at least one treatment outcome in 12 of the 17 studies presented here, and was reported to be significantly effective at promoting cocaine abstinence in a meta-analysis by Levin and Lehman [153] . This limited efficacy of desipramine as a therapeutic is the opposite of what would be predicted by the negative preclinical data obtained in the CPP paradigm, further suggesting that the reinforcing or rewarding effects of a drug are not likely to predict its efficacy as a medication for cocaine addiction.
V.D. 5-HT Involvement
The results from studies investigating the reinforcing and rewarding effects of 5-HT-selective drugs that have been evaluated as potential medications for cocaine addiction were also not as straightforward as the findings with dopaminergic drugs. In contrast to what has been observed with the DA-selective drugs, there were conflicting animal data regarding the potential for misuse of 5-HT selective drugs. In animals, the 5-HT 1A partial agonists buspirone and gepirone did not maintain self-administration, and when paired with a distinct environmental context, failed to condition a place preference in some, but not all studies [156, 167, 154, 159, 155, 158] . Findings from CPP studies with the 5-HTT inhibitor fluoxetine, were equally inconsistent; fluoxetine facilitated the acquisition of CPP in 3 out of the 4 studies that it was tested [171, 170, 172, 173] . In a preliminary study, fluoxetine did not function as a reinforcer in monkeys [169] , consistent with what has been found with other inhibitors of 5-HT transport that have been made available for SA [199, 200, 201] . In contrast, 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) and the methylenedioxy analogues 3,4-methylenedioxyamphetamine (MDA) and 3,4-methylenedioxy-N-ethylamphetamine (MDE) are believed to act primarily at 5-HTT and 5-HT receptors, but maintain responding when made available for self-administration [202, 203, 77, 204] . Likewise, administration of 5-HT-selective agonists has resulted in both positive and negative results in CPP studies [15] .
These inconsistencies regarding the reward-related effects of serotonergic drugs extend to the human literature as well. Of the drugs reviewed here, the 5-HT 1A partial agonists did not have a profile of effects that would indicate significant abuse liability [165, 162, 160, 164, 161, 163] . There were no studies found that specifically investigated the subjective response to fluoxetine and imipramine, however, data from case reports [174, 175, 176] and the DAWN [34] suggested that fluoxetine is not without abuse potential, though the incidence of misuse is probably quite low. Nonetheless, there are several drugs with primary actions at the 5-HT system, such as MDMA and many hallucinogens, that are abused by humans to a much greater extent than what has been reported for fluoxetine. Attempts to use serotonergic drugs to treat cocaine abuse and dependence appeared no more successful than with DA-or NE-selective drugs, in that there were positive results in some, but not all of the clinical trials. The inconsistent effects of 5-HTselective drugs as pharmacotherapies for cocaine addiction are in agreement with the preclinical data indicating that manipulations of 5-HT systems can only partially modulate the behavioral effects of cocaine [11] . There appear to be a number of inconsistencies concerning 5-HT-selective drugs and their potential for abuse and as medications for cocaine addiction. It is evident from these conflicting data that additional research is necessary to elucidate the influence of 5-HT on the behavioral effects of psychostimulants.
V.E. Animal Models and Abuse Liability
The concordance that exists between the results from animal models of the reinforcing and rewarding effects of certain drugs and their recreational use in humans has been previously reported [13, 14, 15] . The comparisons presented here further support the predictive validity of these animal models regarding abuse liability. Nonetheless, while the results from self-administration and conditioned place preference studies in animals appear to be good estimates of the likelihood for misuse of certain drugs in humans, a few inconsistencies have been demonstrated. For example, in addition to the present review, others have pointed out that the DAT blocker mazindol, does not appear to have robust psychostimulant effects in humans although it maintains self-administration and conditions a place preference [205] . Some discussion for this was presented here, however, an imperfect relationship between the findings regarding abuse liability in animal models and humans is not unexpected. As pointed out previously, there are numerous factors, both pharmacological and non-pharmacological, that contribute to the actual prevalence of a drug's abuse potential [18] .
An issue that should be addressed is the data that were used here as an indicator of abuse liability in humans. For the purposes of this study, any positive report of misuse or the potential for misuse from a range of sources was considered to be an indicator of the capacity for abuse. The authors recognize that given the rates of production and appropriate use of the drugs discussed here, the incidence of diversion for many of these drugs is exceedingly small. Furthermore, in order to accurately determine a drug's abuse liability for the purposes of regulating its production, distribution and use, multiple and repeated assessments are necessary. However, the intent of this report was to simply describe the results from the animal literature that pertained to the reinforcing and rewarding effects of these monoamine agonists and determine if there were analogous nominal findings in humans. In that respect, the comparisons made here demonstrate a number of similarities in drug-maintained behavior between animals and humans. Moreover, the discrepancies between the apparent potential for misuse and the actual prevalence of misuse further illustrate how factors other than the inherent psychopharmacological properties of a drug can influence drug-taking behavior.
V.F. Animal Models and Clinical Efficacy
It is generally accepted that there is currently no clinically effective pharmacotherapy for cocaine abuse and dependence. Nonetheless, it was the intent of the authors to provide a thorough review of the clinical literature concerning the utility of monoamine agonist therapies in an attempt to reveal trends suggestive of therapeutic success with a particular drug or class of drugs. However, there appeared to be an equal lack of consistent efficacy with drugs selective for the DA, 5-HT and NE systems. There were both positive and negative reports with candidate medications for cocaine abuse and dependence acting at each of the monoamine systems, but none of these drugs or drug classes appeared to have an obvious advantage or a significant percentage of success over the others. This is in contrast to the results obtained with these drugs in abuse liability assessments, in which the DA-selective drugs were more likely to have the potential for misuse. Thus, while the results from self-administration and conditioned place preference studies in animals offered nominal predictive information regarding the abuse potential of monoamine agonists in humans, they were not accurate estimates of the therapeutic efficacy of those drugs as treatments for cocaine addiction.
Based on the hypothesis that drugs with reinforcing and conditioned rewarding effects similar to cocaine may function as an effective pharmacotherapy by substituting for cocaine, data from CPP and SA studies with monoamine agonists were compared with clinical data to determine if these models were predictive of clinical outcome. Although these animal models did not have predictive validity, there are several other preclinical models of cocaine abuse and dependence that likely provide a better estimation of the potential of candidate medications. For example, pretreatment with DA, 5-HT and NE drugs have been evaluated for their effects on cocaine self-administration under a variety of schedule conditions. The effects of many of the monoamine agonists described here on cocainemaintained behaviors have been reviewed elsewhere [17] . Recently, there has been a shift in focus towards modeling "drug seeking" in addition to evaluating the effects of potential treatments on drug-maintained responding under simple schedules. The use of second-order schedules and the reinstatement paradigm, for example, have allowed for an investigation of the importance of conditioned stimuli in drug addiction [206, 207, 208] . Additionally, the ability of drugs to reverse the heightened stimulus threshold required for intracranial self-stimulation that results from chronic cocaine exposure, considered to be a model of the postcocaine anhedonia typically experienced in abstinent users, may provide an estimation of therapeutic potential [209] . It would be beneficial to assess the predictive validity of these types of animal studies by making comparisons similar to those presented in this review.
V.G. Mixed-Action Drugs
Although inconsistent, there are examples of efficacy with agonists at the DA, 5-HT and NE systems as medications for cocaine abuse and dependence. It is evident that there is at least some form of neuroadaptive change in each of these systems following chronic cocaine intake [210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220] . Because the dysregulation of each system could mediate different aspects of cocaine addiction, a more appropriate treatment strategy may be to use mixed-action drugs that target more than one type of neurotransmitter. Several open studies and one controlled clinical trial were found that have attempted this approach using a combination of monoamine agonists. Notably, in a double-blind, placebo-controlled trial, Giannini and Billet [134] demonstrated that bromocriptine and desipramine, when administered together, were more effective at alleviating cocaine withdrawal symptoms than bromocriptine alone or placebo. Other combinations that have proven successful in open trials include phentermine and fenfluramine [221, 222] , pemoline and fenfluramine [223] and a stepwise detoxification program that included amantadine, tyrosine, tryptophan, l-dopa, bromocriptine and desipramine [224] . Moreover, although d-amphetamine was listed with the DA-selective compounds, it is, in fact, a potent releaser of all three monoamines and could thus be considered a mixed-action treatment. The recent success with d-amphetamine as a cocaine pharmacotherapy [59] further supports the continued development of medications directed at the DA, 5-HT and NE systems. Still, there are also negative findings with mixed-action or combined drug treatments. Kampman and Volpicelli [222] reported that detrimental effects were observed following administration of methylphenidate and fluoxetine. Furthermore, mazindol inhibits the reuptake of 5-HT and NE in addition to its effects at DAT and can also be considered a mixed-action drug. Results from clinical studies investigating the potential of mazindol as a medication for cocaine addiction, however, were much less promising than the initial findings with damphetamine [110, 109, 111, 108, 112] .
V.H. Future Considerations
There are data that suggest that NE and 5-HT can influence the reinforcing and rewarding effects of cocaine and other drugs. However, it is evident that DA is the neurotransmitter primarily involved in mediating these effects for cocaine and other psychostimulants. In contrast, the results from clinical studies that have evaluated monoamine agonists as candidate medications for cocaine addiction indicate that each of these neurotransmitter systems is important with respect to the long-term consequences of cocaine use. Further research is necessary in the continued investigation of the specific mechanisms by which cocaine exerts its behavioral effects and to determine the extent that DA, 5-HT and NE reuptake inhibition is involved both acutely and chronically. Several series of cocaine analogs with varied affinities and selectivities for monoamine transporters have been developed that allow for the systematic study of their involvement [225, 226, 227] . One medications development strategy being investigated preclinically is the use of long-acting monoamine transporter inhibitors with a slower onset and prolonged duration of action which may be less efficacious as a reinforcer than cocaine [187] . Additionally, the synthesis of compounds that target the receptor subtypes of the central DA, 5-HT and NE systems with even greater specificity will advance our understanding of the down-stream mediators of increased synaptic concentrations of these monoamines. These selective drugs, along with better characterized compounds, can be studied in animal models of drug abuse, and in humans as well, in an effort to understand the neurobiological basis for addiction and to screen for potential therapeutics for cocaine abuse and dependence. Finally, the data collected from the preclinical and clinical studies should then be compared, as was done here, and used to identify animal models that are accurate predictors of the human condition and as a guide to modify existing procedures and aid in the development of novel strategies. 
